LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer

Autor:	Cristina Saura, Evandro De Azambuja, Mafalda Oliveira, Peter Christian Dubsky, Dimitrios Zardavas, Christian Fesl, Aditya Bardia, Jesus Soberino, Monica N. Fornier, Katalin Boer, Vivian Ng, Jill O. Fredrickson, Thomas Stout, Stina Singel, Jerry Y. Hsu, Martine J. Piccart-Gebhart, Jose Baselga, Michael Gnant
Rok vydání:	2016
Předmět:	Oncology Cancer Research medicine.medical_specialty Postmenopausal women business.industry Letrozole 010401 analytical chemistry HER2 negative Alpha (ethology) Placebo medicine.disease 01 natural sciences 0104 chemical sciences Double blind study 03 medical and health sciences 0302 clinical medicine Endocrinology Breast cancer 030220 oncology & carcinogenesis Internal medicine medicine Stage (cooking) business medicine.drug
Zdroj:	Journal of Clinical Oncology. 34:TPS613-TPS613
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2016.34.15_suppl.tps613
Popis:	TPS613Background: Taselisib is an orally bioavailable, potent, selective inhibitor of Class I PI3-kinase (PI3K) alpha, gamma, and delta isoforms, with 30-fold less inhibition of the PI3K beta isofo...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ae902c3ff769f85acc4de63ff3510618 https://doi.org/10.1200/jco.2016.34.15_suppl.tps613 Zobrazit plný text záznamu